Cutar Alzheimer
| Cutar Alzheimer | |
|---|---|
 | |
Description (en)  | |
| Iri |
tauopathy (en) , aging-associated disease (en) cuta |
| Specialty (en) |
neurology (en) |
| Sanadi |
unknown (en) |
| Symptoms and signs (en) |
memory loss that disrupts daily life (en) , confusion with time and space (en) , challenges in planning or solving problems (en) , difficulty completing familiar tasks at home, at work or at leisure (en) , trouble understanding visual images and spatial relationships (en) , decreased or poor judgment (en) , withdrawal from work or social activities (en) , problems with words in speaking or writing (en) , changes in mood and personality (en) , misplacing things and losing the ability to retrace steps (en) Dementia |
| Physical examination (en) |
neurological diagnostic techniques (en) , medical history (en) , magnetic resonance imaging (en) , psychological test (en) genetic testing (en) |
| Genetic association (en) |
APOE (en) , NKAIN2 (en) , BMPER (en) , SLC8A1-AS1 (en) , MS4A3 (en) , CR1 (en) , CD2AP (en) , ABCA7 (en) , INPP5D (en) , ZCWPW1 (en) , CELF1 (en) , FERMT2 (en) , CASS4 (en) , PTK2B (en) , SORL1 (en) , SQSTM1 (en) , NDUFAF6 (en) , AP2A2 (en) , IGH (en) , SPPL2A (en) , TRIP4 (en) , CD33 (en) , GLIS3 (en) , PRRC2C (en) , FMN2 (en) , CTNNA2 (en) , LIMS2 (en) , MOBP (en) , STK32B (en) , AFF1 (en) , ANKRD55 (en) , CAMK4 (en) , DMXL1 (en) , MEGF10 (en) , SAP30L (en) , PLEKHG1 (en) , CYCS (en) , ELMO1 (en) , HECW1 (en) , EXOC4 (en) , CSMD1 (en) , ST18 (en) , NCS1 (en) , PLPP4 (en) , ARHGAP20 (en) , SLC4A8 (en) , CRADD (en) , ANO4 (en) , GPC6 (en) , MYO16 (en) , CLMN (en) , GABRG3 (en) , VAT1L (en) , CACNA1G (en) , BCAS3 (en) , PPIAP59 (en) , TGM6 (en) , PARVB (en) , APOC1 (en) , NECTIN2 (en) , TOMM40 (en) , TREM2 (en) , MPZL1 (en) , ATXN7L1 (en) , LUZP2 (en) , CDON (en) , PCNX1 (en) , PICALM (en) , PPP1R3B (en) , SLC4A1AP (en) , POLN (en) , CNTNAP2 (en) , STK24 (en) , VSNL1 (en) , BIN1 (en) , MPP7 (en) , ZNF320 (en) , STK11 (en) , DIP2C (en) , DCHS2 (en) , CLU (en) , CCDC134 (en) , MTHFD1L (en) , RELN (en) , PCDH11X (en) , GAB2 (en) , APP (en) da PLD3 (en) |
| Suna saboda |
Alois Alzheimer (en) |
| Medical treatment (en) | |
| Magani |
quetiapine (en) , aripiprazole (en) , galantamine (en) , donepezil (en) , risperidone (en) , memantine (en) , rivastigmine (en) , rivastigmine (en) , memantine (en) da pyritinol (en) |
| Identifier (en) | |
| ICD-10-CM | G30.9 da G30 |
| ICD-9-CM | 331.0 da 290.1 |
| OMIM | 104300 |
| DiseasesDB | 490 |
| MedlinePlus | 000760 |
| eMedicine | 000760 |
| MeSH | D000544 |
| GeneReviews | NBK1161 |
| Disease Ontology ID | DOID:10652 |
Cutar Alzheimer (AD), kuma ana kiranta da kawai Alzheimer's, cuta ce ta neurodegenerative na yau da kullun wacce yawanci ke farawa sannu a hankali kuma a hankali yana ta'azzara akan lokaci.[1][2] Shi ne sanadin kashi 60-70% na lamurra na hauka.[1][2] Alamar farko ta gama gari ita ce wahala wajen tunawa da abubuwan da suka faru kwanan nan.[1] Yayin da cutar ke ci gaba, alamun na iya haɗawa da matsaloli tare da harshe, rashin tunani (ciki har da samun sauƙi a ɓace), sauye-sauyen yanayi, asarar dalili, rashin kula da kai, da kuma al'amurran halayya.[1][2] Yayin da yanayin mutum ya ragu, sau da yawa yakan janye daga iyali da kuma al'umma.[1] A hankali, ayyukan jiki suna ɓacewa, a ƙarshe yana haifar da mutuwa.[3] Ko da yake saurin ci gaba na iya bambanta, yanayin rayuwa na yau da kullun bayan ganewar asali shine shekaru uku zuwa tara.[4][5]
Ba a fahimci dalilin cutar Alzheimer ba.[1] Kusan kashi 70 cikin 100 na haxarin an yi imanin gadon su ne daga iyayen mutum, tare da yawancin kwayoyin halitta.[6] Sauran abubuwan haɗari sun haɗa da tarihin raunin kai, damuwa, da hauhawar jini.[1] Tsarin cutar yana hade da plaques da neurofibrillary tangles a cikin kwakwalwa.[6] Mahimmin ganewar asali yana dogara ne akan tarihin rashin lafiya da gwajin tunani tare da hoton likita da gwajin jini don kawar da wasu dalilai masu yiwuwa.[7] Alamun farko galibi ana kuskure da tsufa na al'ada.[1] Ana buƙatar gwajin ƙwayar ƙwayar ƙwayar cuta don takamaiman ganewar asali.[6] motsa jiki na tunani da na jiki, da nisantar kiba na iya rage haɗarin AD; duk da haka, shaidun da ke goyan bayan waɗannan shawarwarin suna da rauni.[6][8] Babu magunguna ko kari waɗanda aka nuna don rage haɗari.[9]
Babu wani magani da zai dakatar ko mai da ci gabansa, kodayake wasu na iya inganta alamun na ɗan lokaci.[2] Mutanen da abin ya shafa suna ƙara dogara ga wasu don taimako, galibi suna dora nauyi kan mai kulawa.[10] Matsanancin na iya haɗawa da zamantakewa, tunani, jiki, da abubuwan tattalin arziki.[10] Shirye-shiryen motsa jiki na iya zama masu fa'ida game da ayyukan rayuwar yau da kullun kuma suna iya haɓaka sakamako.[11] Matsalolin ɗabi'a ko ciwon hauka saboda ciwon hauka galibi ana bi da su tare da magungunan kashe qwari, amma wannan ba yawanci ana ba da shawarar ba, saboda ƙarancin fa'ida da haɗarin mutuwa da wuri.[12][13]
A cikin 2015, akwai kusan mutane miliyan 29.8 a duk duniya tare da AD.[2][14] Yawancin lokaci yana farawa a cikin mutane sama da shekaru 65, kodayake kashi 4-5% na lokuta ne farkon farkon cutar Alzheimer.[15] Yana shafar kusan kashi 6% na mutane masu shekaru 65 da haihuwa.[1] A cikin 2015, ciwon hauka ya haifar da mutuwar kusan miliyan 1.9.[16] An fara bayyana ta ne daga baya, daga baya, masanin ilimin halin dan Adam na kasar Jamus Alois Alzheimer a shekarar 1906.[17] A kasashen da suka ci gaba, AD na daya daga cikin cututtuka masu tsadar kudi.[18][19]
Manazarta
[gyara sashe | gyara masomin]- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 Burns A, Iliffe S (February 2009). "Alzheimer's disease". BMJ. 338: b158. doi:10.1136/bmj.b158. PMID 19196745. S2CID 8570146.
- ↑ 2.0 2.1 2.2 2.3 2.4 "Dementia Fact sheet". World Health Organization. 12 December 2017.
- ↑ "About Alzheimer's Disease: Symptoms". National Institute on Aging. Archived from the original on 15 January 2012. Retrieved 28 December 2011.
- ↑ Querfurth HW, LaFerla FM (January 2010). "Alzheimer's disease". The New England Journal of Medicine. 362 (4): 329–44. doi:10.1056/NEJMra0909142. PMID 20107219. S2CID 205115756.
- ↑ Todd S, Barr S, Roberts M, Passmore AP (November 2013). "Survival in dementia and predictors of mortality: a review". International Journal of Geriatric Psychiatry. 28 (11): 1109–24. doi:10.1002/gps.3946. PMID 23526458.
- ↑ 6.0 6.1 6.2 6.3 Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (March 2011). "Alzheimer's disease". Lancet. 377 (9770): 1019–31. doi:10.1016/S0140-6736(10)61349-9. PMID 21371747.
- ↑ "Dementia diagnosis and assessment" (PDF). National Institute for Health and Care Excellence (NICE). Archived from the original (PDF) on 5 December 2014. Retrieved 30 November 2014.
- ↑ "So, What Can You Do?". National Institute on Aging. 29 July 2016. Archived from the original on 3 April 2017.
- ↑ Hsu D, Marshall GA (2017). "Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward". Current Alzheimer Research. 14 (4): 426–40. doi:10.2174/1567205013666160930112125. PMC 5329133. PMID 27697063.
- ↑ 10.0 10.1 Thompson CA, Spilsbury K, Hall J, Birks Y, Barnes C, Adamson J (July 2007). "Systematic review of information and support interventions for caregivers of people with dementia". BMC Geriatrics. 7: 18. doi:10.1186/1471-2318-7-18. PMC 1951962. PMID 17662119.
- ↑ Forbes D, Forbes SC, Blake CM, Thiessen EJ, Forbes S (April 2015). "Exercise programs for people with dementia". The Cochrane Database of Systematic Reviews (Submitted manuscript). 132 (4): CD006489. doi:10.1002/14651858.CD006489.pub4. PMID 25874613.
- ↑ National Institute for Health and Clinical Excellence. "Low-dose antipsychotics in people with dementia". National Institute for Health and Care Excellence (NICE). Archived from the original on 5 December 2014. Retrieved 29 November 2014.
- ↑ "Information for Healthcare Professionals: Conventional Antipsychotics". US Food and Drug Administration. 16 June 2008. Archived from the original on 29 November 2014. Retrieved 29 November 2014.
- ↑ GBD 2015 Disease Injury Incidence Prevalence Collaborators (October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC 5055577. PMID 27733282.
- ↑ Mendez MF (November 2012). "Early-onset Alzheimer's disease: nonamnestic subtypes and type 2 AD". Archives of Medical Research. 43 (8): 677–85. doi:10.1016/j.arcmed.2012.11.009. PMC 3532551. PMID 23178565.
- ↑ GBD 2015 Mortality Causes of Death Collaborators (October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1459–1544. doi:10.1016/S0140-6736(16)31012-1. PMC 5388903. PMID 27733281.
- ↑ Berchtold NC, Cotman CW (1998). "Evolution in the conceptualization of dementia and Alzheimer's disease: Greco-Roman period to the 1960s". Neurobiology of Aging. 19 (3): 173–89. doi:10.1016/S0197-4580(98)00052-9. PMID 9661992.
- ↑ Bonin-Guillaume S, Zekry D, Giacobini E, Gold G, Michel JP (January 2005). "[The economical impact of dementia]". Presse Médicale (in French). 34 (1): 35–41. doi:10.1016/s0755-4982(05)83882-5. PMID 15685097.CS1 maint: unrecognized language (link)
- ↑ Meek PD, McKeithan K, Schumock GT (1998). "Economic considerations in Alzheimer's disease". Pharmacotherapy. 18 (2 Pt 2): 68–73, discussion 79–82. doi:10.1002/j.1875-9114.1998.tb03880.x (inactive 2020-05-25). PMID 9543467. Archived from the original on 2019-10-16. Retrieved 2022-02-03.CS1 maint: DOI inactive as of Mayu 2020 (link)